Eva-Lotta Allan
Director/Board Member at ALMIRALL, S.A.
Network origin in Eva-Lotta Allan first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 26 | |
18
| Subsidiary | Biotechnology | 18 |
| Public Company | Biotechnology | 11 | |
Crescendo Biologics Ltd.
 Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom.
9
| Holding Company | Miscellaneous Commercial Services | 9 |
| Public Company | Pharmaceuticals: Major | 7 | |
Maxion Therapeutics Ltd.
 Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation.
7
| Holding Company | Pharmaceuticals: Major | 7 |
Draupnir Bio ApS
 Draupnir Bio ApS Pharmaceuticals: MajorHealth Technology Draupnir Bio ApS engages in the manufacture and distribution of biotechnological and pharmaceutical products. It also provides medical research services. The company was founded on April 4, 2017 and is headquartered in Risskov, Denmark.
5
| Holding Company | Pharmaceuticals: Major | 5 |
Vertex Pharmaceuticals (Europe) Ltd.
 Vertex Pharmaceuticals (Europe) Ltd. Medical DistributorsDistribution Services Vertex Pharmaceuticals (Europe) Ltd. operates as a pharmaceutical firm. The company was founded on March 11, 1994 and is headquartered London, the United Kingdom.
2
| Subsidiary | Medical Distributors | 2 |
Aleta Biotherapeutics, Inc.
 Aleta Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aleta Biotherapeutics, Inc. engages in the immuno-oncology service that focuses on transforming cellular therapeutics. It allows broad spectrum of cancer indication to be targeted including currently intractable solid tumors. The company was founded by Paul Rennert and Roy Lobb and is headquartered in Natick, MA.
2
| Holding Company | Miscellaneous Commercial Services | 2 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Eva-Lotta Allan via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| JOHNSON & JOHNSON | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Comptroller/Controller/Auditor Corporate Officer/Principal Corporate Officer/Principal | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal Corporate Officer/Principal | |
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Pharmaceuticals: Generic | Director/Board Member Director of Finance/CFO Corporate Officer/Principal | |
MedImmune Ltd.
 MedImmune Ltd. BiotechnologyHealth Technology MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Founder Corporate Officer/Principal | |
| GALAPAGOS NV | Biotechnology | Chairman Director/Board Member | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Fujirebio Europe NV
 Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Medical Specialties | Director of Finance/CFO Chief Tech/Sci/R&D Officer | |
| University of Oxford | College/University | Corporate Officer/Principal Doctorate Degree Graduate Degree Corporate Officer/Principal Undergraduate Degree Doctorate Degree Graduate Degree Doctorate Degree | |
| Imperial College London | College/University | Graduate Degree Graduate Degree | |
| The University of Manchester | College/University | Doctorate Degree Doctorate Degree | |
| University of Glasgow | College/University | Doctorate Degree Undergraduate Degree | |
Sofinnova Partners SAS
 Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Investment Managers | Private Equity Investor Private Equity Investor | |
| University of Cambridge | College/University | Undergraduate Degree Doctorate Degree Graduate Degree Graduate Degree | |
| University of Birmingham | College/University | Doctorate Degree Doctorate Degree | |
CropDesign NV
 CropDesign NV Miscellaneous Commercial ServicesCommercial Services CropDesign NV develops traits for cereal crops. It delivers agronomic traits for the global commercial seed markets. The firm focuses on enhancing grain yield in crops such as corn and rice, and increasing biomass of energy crops. Its platform, TraitMill, lows evaluating the effect of genes on the performance of plants under different growing conditions, including drought and low nutrient stress. The company was founded in 1998 and is headquartered in Zwijnaarde, Blgium. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
deVGen NV
 deVGen NV BiotechnologyHealth Technology deVGen NV provides biotechnology services for the pharmaceutical and agrochemical industries. It innovates in crop protection research and environment induced stress tolerance for its own crops and provides technology to corporate partners. The firm produces and sells its hybrid seeds in field crops such as rice, sunflower, sorghum and pearl millet in the Indian subcontinent and Southeast Asia. The company was founded by Thierry Bogaert on September 10, 1997 and is headquartered in Ghent, Belgium. | Biotechnology | Chairman Director/Board Member | |
Chroma Therapeutics Ltd.
 Chroma Therapeutics Ltd. BiotechnologyHealth Technology Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Chairman Chairman | |
| University of Barcelona | College/University | Doctorate Degree Masters Business Admin Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| Ghent University | College/University | Corporate Officer/Principal Graduate Degree Doctorate Degree | |
| Universitat Pompeu Fabra | College/University | Masters Business Admin Corporate Officer/Principal | |
| AVACTA GROUP PLC | Miscellaneous Commercial Services | Director/Board Member Chairman Director/Board Member Chief Executive Officer | |
MyCartis NV
 MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium. | Biotechnology | Chairman Director/Board Member Chairman | |
Intrexon ActoBiotics NV
 Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | Biotechnology | Director/Board Member Director/Board Member | |
Academy of Medical Sciences
 Academy of Medical Sciences Miscellaneous Commercial ServicesCommercial Services The Academy of Medical Sciences was founded in 1998 and provides biomedical and health research services. The non-profit company is based in London, UK. | Miscellaneous Commercial Services | Corporate Officer/Principal President | |
European Federation of Pharmaceutical Industries & Assns
 European Federation of Pharmaceutical Industries & Assns Miscellaneous Commercial ServicesCommercial Services The European Federation of Pharmaceutical Industries & Assns is a trade association that promotes pharmaceutical discovery and development. The non-profit company is based in Brussels, Belgium. | Miscellaneous Commercial Services | President President Director/Board Member Director/Board Member | |
Heptares Therapeutics Ltd.
 Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chairman Corporate Officer/Principal | |
AstraZeneca, Inc.
 AstraZeneca, Inc. BiotechnologyHealth Technology Part of AstraZeneca PLC, AstraZeneca, Inc. manufactures vaccines. | Biotechnology | Director/Board Member President | |
The Bioindustry Association
 The Bioindustry Association Miscellaneous Commercial ServicesCommercial Services The BioIndustry Association is a UK-based organization that represents the life sciences and biotech industry. The British company's mission is to facilitate and connect the ecosystem to help businesses start, grow, and deliver world-changing innovation. The non-profit company was founded by Cormac G. Kilty and Simon Geoffrey Best, and Steve Bates has been the CEO of the company since 2012. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member | |
Bird Rock Bio, Inc.
 Bird Rock Bio, Inc. BiotechnologyHealth Technology Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA. | Biotechnology | Chairman Director/Board Member | |
Complix NV
 Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
| Albert Einstein College of Medicine, Inc. | College/University | Doctorate Degree Doctorate Degree | |
Biocartis SA
 Biocartis SA Medical SpecialtiesHealth Technology Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland. | Medical Specialties | Director/Board Member Chief Tech/Sci/R&D Officer | |
C4X Discovery Ltd.
 C4X Discovery Ltd. Pharmaceuticals: MajorHealth Technology C4X Discovery Ltd. engages in the discovery and development of medical drugs. It uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. The company was founded by Andrew Almond and Charles Douglas Blundell in January 2008 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chairman Chief Tech/Sci/R&D Officer | |
Pulmagen Therapeutics LLP
 Pulmagen Therapeutics LLP Pharmaceuticals: MajorHealth Technology Pulmagen Therapeutics Ltd. manufactures and develops respiratory drugs. Its services include pulmagen respiratory product pipeline, pulmagen crth2 antagonist product pipeline, new generation bronchodilators-astrazeneca collaboration, theocort-inhaled corticosteroid re-sensitisation, inhaled ppar gamma agonists and chiesi collaboration-anti-inflammatory agents. The company was founded in February 2010 and is headquartered in Slough, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Akamis Bio Ltd.
 Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Director/Board Member Director of Finance/CFO Director/Board Member | |
| University of Antwerp | College/University | Graduate Degree Graduate Degree Doctorate Degree | |
| Stanford Graduate School of Business | College/University | Graduate Degree Masters Business Admin | |
Genomics England Ltd.
 Genomics England Ltd. Miscellaneous Commercial ServicesCommercial Services Genomics England Ltd. runs and delivers 100,000 genomes project. Its flagship project sequences 100,000 genomes from NHS patients with a rare disease and their families, and patients with cancer. The company was founded by Jeremy Hunt on July 5, 2013 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Levicept Ltd.
 Levicept Ltd. Pharmaceuticals: GenericHealth Technology Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom. | Pharmaceuticals: Generic | Director/Board Member Chief Executive Officer | |
| BIOCARTIS GROUP NV | Medical Specialties | Director/Board Member Chief Tech/Sci/R&D Officer | |
| SEQUANA MEDICAL N.V. | Medical Specialties | Director/Board Member Director/Board Member | |
Pheno Therapeutics Ltd.
 Pheno Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Pheno Therapeutics Ltd. operates as a biotechnology company. The firm develops remyelinating therapies for the unmet need for a neuroprotective therapy for multiple sclerosis. The company was founded on October 31, 2018 and is headquartered in Edinburgh, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| F-STAR THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Corporate Officer/Principal | |
Immunocore Ltd.
 Immunocore Ltd. Pharmaceuticals: MajorHealth Technology Part of Immunocore Holdings Plc, Immunocore Ltd. is a British commercial-stage biotechnology company that develops and commercializes transformative medicines to address unmet needs in cancer, infection, and autoimmune disease. The private company is based in Oxon, UK. The company has a robust pipeline of wholly owned and partnered programs to address a broad spectrum of disease indications, built on their proprietary soluble TCR bi-specific Immtac® platform. The company was founded in 2007, and the CEO is Bahija Jallal. | Pharmaceuticals: Major | Director of Finance/CFO Chief Executive Officer Director/Board Member |
Statistics
International
| United Kingdom | 24 |
| Belgium | 13 |
| United States | 8 |
| Israel | 3 |
| Spain | 3 |
Sectoral
| Health Technology | 31 |
| Consumer Services | 13 |
| Commercial Services | 8 |
| Finance | 2 |
Operational
| Director/Board Member | 569 |
| Corporate Officer/Principal | 162 |
| Chairman | 117 |
| Independent Dir/Board Member | 80 |
| Chief Executive Officer | 70 |
Most connected contacts
| Insiders | |
|---|---|
| Raj Bhikhu Parekh | 50 |
| Enrique de Leyva Pérez | 44 |
| James Noble | 39 |
| Eliot Forster | 35 |
| Russell Greig | 31 |
| Roel Bulthuis | 29 |
| Rudy Dekeyser | 29 |
| Thomas Fulton Wilson McKillop | 28 |
| Samuel Cameron Williams | 27 |
| John Bell | 27 |
| Graziano Seghezzi | 26 |
| Denis Lucquin | 26 |
| Shah Hussain | 25 |
| John Berriman | 24 |
| Mats Gunnar Pettersson | 23 |
- Stock Market
- Insiders
- Eva-Lotta Allan
- Company connections
